[ad_1]
Researchers have identified three subtypes of lung cancer in non-smokers with the disease, who make up about 10-20% of the lung cancer patient population, according to the National Institutes of Health. The tumors of non-smokers were found to originate from mutations induced by natural bodily processes, the agency said.
Lung cancer is considered the leading cause of cancer-related deaths worldwide, and more than 2 million people are diagnosed worldwide each year. The results published in Nature Genetics involved sequencing the entire genome of tumor tissue against normal tissue of 232 never-smokers diagnosed with non-small cell lung cancer, and who had not yet received treatment.
FAUCI OVER COVID-19: UNITED STATES LACKS “MODESTLY GOOD CONTROL” OVER PANDEMIC
“What we are finding is that there are different subtypes of lung cancer in non-smokers that have distinct molecular characteristics and evolutionary processes,” said Dr Maria Teresa Landi, head of the researcher and epidemiologist in the Division of Cancer Epidemiology and Genetics at the National Cancer Institute. said in a statement. “In the future, we may be able to have different treatments based on these subtypes.”
KATHY GRIFFIN LUNG CANCER DIAGNOSIS: ARE NON-SMOKERS AT RISK?
To conduct the study, an international team of researchers led by the National Cancer Institute examined tumor genomes for patterns of mutations linked to mutational processes such as exposure to carcinogens, oxidative stress, or faulty repair. DNA, which could help explain the cause of cancer. The results indicated that most mutations in people who never smoked came from natural processes that occur in the body.
The three new lung cancer subtypes have been classified according to the number of genomic changes; the first subtype was reported to be difficult to treat and grows slowly over the years, while the second stimulated faster tumor growth and the third exhibited a genomic change seen in lung cancer in smokers. The third subtype is also said to have grown rapidly.
CLICK HERE TO GET THE FOX NEWS APP
“We are starting to distinguish subtypes that could potentially have different approaches to prevention and treatment,” Landi added. The first subtype may offer a chance for earlier detection while the other two could be found with a single biopsy and improve with targeted treatments, Landi said.
[ad_2]
Source link